Glaucoma subspecialists were more likely to choose SLT than other ophthalmologists. 

Glaucoma is one of the leading causes of irreversible blindness worldwide, accounting for 11% of global blindness in 2020. The Royal Australian College of General Practitioners (RACGP) notes glaucoma to be the second leading cause of irreversible blindness in Australians aged over 55, following age-related macular degeneration, with over half of cases remaining undiagnosed.

Published in Scientific Reports on 15 October 2026, the study found 59% of respondents preferred prostaglandin analogues for progressive primary open-angle glaucoma (POAG), while 39% selected SLT. A further 2% favoured topical beta blockers.

Treatment preferences varied according to clinicians’ experience and subspecialty. Glaucoma subspecialists were more likely to choose SLT than other ophthalmologists (48% compared with 28%), while non-glaucoma subspecialists were more likely to favour prostaglandin analogues (73% compared with 49%).

Ophthalmologists with less than 10 years of experience were more likely to select SLT as first-line treatment than those with at least 10 years in practice (59% compared with 31%). Experienced practitioners showed a stronger preference for prostaglandin analogues.

For progressive normal-tension glaucoma (NTG), prostaglandin analogues remained the most common first-line treatment, selected by 73% of respondents, followed by SLT at 23% and alpha-2 agonists (325).

The findings come from a 21-question online survey, with respondents including 114 Australian and 21 New Zealand ophthalmologists. 57% of respondents identified as glaucoma subspecialists.

The study also identified the adoption of minimally invasive glaucoma surgery (MIGS), with 86% of respondents reporting they performed the procedures.

Among the 116 ophthalmologists who performed MIGS, 43% implemented it during cataract surgery in all POAG cases, while 42% reserving it in cases of progression, suboptimal intraocular pressure (IOP) control or medication intolerance.

Trabecular bypass stents were the most selected MIGS procedures, with 91% of respondents performing MIGS reporting use of iStent and 22% using Hydrus.

Trabeculectomy was the preferred first-line procedure for patients requiring incisional glaucoma surgery, selected by 63% of the 97 respondents who performed this type of surgery. Glaucoma drainage devices were the most common second-line choice selected by 52%.

The survey respondents reported greater use of OCT, SLT and MIFS, compared with surveys conducted approximately two decades earlier, the researchers noted.

While prostaglandin analogues remained the most common first-line treatment for POAG, their preference had declined from 82% in earlier surveys to 59%.

The researchers also reported greater adoption of OCT, with 98% of respondents using the technology, compared with less than 1% in previous surveys. MIGS, which was not available during the earlier surveys, was now performed by 86% of respondents.

However, findings reflect self-reported practice and may not represent the wider profession, with glaucoma subspecialists accounting for 57% of respondents. by Fatemeh Mirjalili – Insight News

Share
Previous Next